Join us at Health Research Day — June 6th at Canton Waterfront Park, Baltimore!   Learn More →
← Back to all trials
Completed NCT00761631

Study Evaluating 13-valent Pneumococcal Conjugate Vaccine (13vPnC) in Healthy Children Aged 15 Months to 17 Years

Conditions: Healthy Subjects

Sex: All
Ages: 15 Months – 18 Years
Healthy volunteers: No
Phase: PHASE3
Enrollment: 1200
Sponsor: Pfizer

Location: Central Arkansas Pediatric Clinic Benton Arkansas

Summary

This open-label, multicenter study is designed to evaluate the safety, tolerability and immunogenicity of 13-valent pneumococcal conjugate vaccine in healthy children aged more than 15 months up to less than 18 years.

Eligibility Criteria

Inclusion Criteria: * Male or female subjects \>15months to \

Interested in this study? View the official listing for contact and enrollment details.

View on ClinicalTrials.gov

Source: ClinicalTrials.gov (NCT00761631). StuddyBuddy aggregates publicly available trial information.